Member Info for RayPointer

"Now come on Ichor!" indeed

You would have thought they would be pulling out all the stops to get their IND approved. Surely, it's got to be their priority to gain access to the US market.

As far as I can see the version 2 device has already been approved for 2 trails outside the US

https://www.businesswire.com/news/home/20180604005232/en/

https://www.businesswire.com/news/home/20180821005144/en/Ichor-Medical-Systems-Announces-Utilization-Investigational-TriGrid

No problems Chelsea. I always meant to check out the opposition.
I would be really surprised if we didn't win.

Yes, but it's great that he has tipped us off about Scancell's demise.
I'm going to send him a bone for Christmas.

Well it looks like

1) Scancell will lose the GC
2) Biontech will pull out of the collaboration
3) The planned trials will not happen
4) Lindy will take that job at VAL

LOL

Project Blueprint

a) A new vaccine MODI3 for several hard to treat cancers with poor prognoses
b) If the vaccine fails the project inclues diagnostics to determine the
best targets for the cancer
c) TCR treatment for those patients that do not respond to Modi3 the vaccine

This is the only contestant that actually sets out to cure certain cancers albeit using a
yet to be developed vaccine.
Obviously it all hinges on Modi3 being effective but, as we already know, Lindy's work
is well known to CRUK. As we have discovered recently, Scancell's relationship with CRUK goes back a long way.

The project includes some of the leading lights in the cancer immunotherapy scene.
It is also noticable that Lindy's team has the biggest contingent from biotech companies
- 4 to be exact (Scancell, ISA pharma, BionTech and Genetech). The nearest the other
contestants come to this is only 1.

Project Blueprint long term prospects

Lindy has said twice now in presentations that her ambition is to cure all cancers.
Could Project Blueprint be why she has started saying this?
Should PBP be successful based on Modi3, then IMO it will not end there. It is entirely logical to extend the project to include Modi1 and Modi2.

But why stop there? Why not also add immunobody vaccines to the project?
These may well be the goto vaccines for early stage cancers and/or patients with resected tumours.
Perhaps CIs will also figure in the mix in combo with immunobody.

Also see what Lindy herself says about PBP

"We believe this approach will facilitate the development of a comprehensive strategy of combinatorial cancer treatment for patients with most types of cancer.
Our unique academic-biotech-clinical partnership, facilitating access to reagents and clinical trials, positions us for success in this space"

about delivery

"Alongside this, the team will be testing a variety of ways of delivering the treatment to make sure that their vaccine gets to the tumour as efficiently as possible."

Lindy was one of the first users of Trigrid and maybe the first, and now she have moved on to nano vesicles for the SCIB2 trial.
She understands the importance of efficient vaccine delivery.

https://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-challenge-award/shortlistedteamdurrant

This is all predicated on Lindy's vaccines being successful, but it is the obvious ambition and scope of PBP that makes it well ahead of the opposition IMO.
In fact I would say it is streets ahead.

https://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-challenge-award/round-2-shortlisted-teams

GC contestants (apart from blueprint) with categories

1) Uncovering how obesity causes cancer
Cancer causes
2) Unravelling how chronic inflammation causes cancer
Cancer causes
3) A new way to tackle inflammation-associated cancer
Cancer causes
4) Looking out for cancer
Artificial Intelligence
5) Mining medical records for early signs of cancer
Artificial Intelligence
6) Eliminating sleeping cancer cells
Dormancy
7) Dissecting the tumour specificity of cancer drivers
Tissue Specificity
8) Working smarter, not harder: improving treatment combinations
Treatment Regimens
9) Bugs, guts & cells: beating gastrointestinal cancer
Microbiota

All fine projects in their own right but
a) none are specifically concerned with creating new treatments although
the knowledge gained may lead to new treatments
b) they are either
aimed at increasing our knowledge of cancer causes (1-3)
or
creating AI programs to help diagnose early cancer signs (4-5)
or
studying how cancer can re-appear (6)
or
better understanding of how to select the best existing treatments for
individual patients (7-8)
or
studying how microbiota influence development of bowel cancer

I also have the following comments:

Projects 2 and 3 both concerned with inflammation
One of the facets of immunobody is that the CD4 helper cells induce imflammation at the tumour site.
This leaves the tumour vunerable to attack by the CD8 cells.
This suggests Lindy has got a good handle of how to take advantage of inflammation
to effect a potent attack.
CRUK will know this as they are paying for the SCIB2 trial

Projects 4 and 5 Early signs of cancer
Scancell think that Immunobody may also be effective in treating early stage cancer

"Patients with early-stage disease and reduced tumour burden may be more able to mount a
robust immune response than late-stage patients with bulky disease"

https://www.proactiveinvestors.co.uk/upload/SponsorFile/File/2016_07/Scancell-Presentation-July-2016-(1).pdf

Project 6 Dormancy
Immunobody (SCIB1) has already shown a memory effect in humans.
Moditope is also expected to have a memory effect. It does in mice and it
goes down the same basic route as Immunobody by APC ingestion, TCell activation and
clonal expansion.
So Moditope is expected to solve the problem in a natural and much more effective way as
it has already been proved with Immunobody (SCIB1).

Projects 7) and 8)
Diagnostics are central to these 2 projects
Project blueprint also includes diagnostics as part of the project (Genentech and Biontech)
That is not to say that these 2 projects would turn out to be superior to Genetech's
and Biontech's work.

Yes, I did.
I just need to do a bit more research and then I will post

The eye of big pharma is for ever watching LOL

https://www.youtube.com/watch?v=RKk8mb0Z3Jg

Yes, I agree with all you say.
Additionally, a BionTech deal or deals could well mean the end of dilution.
This obviously depends on the timing and the up front amount.

It is always hard to predict share price movement of small companies and Scancell being a small biotech makes it even harder.
However, a GC win and a Biontech deal looks like it could be the possible inflection point we have all been patiently awaiting. So don't discount 2019 as being the year everything starts to happen SP-wise.

Noise

Excellent that you are continuing comparisons with competitors
Recommended

Proper butties, not salmon paste!

Lindy won't be sharing hers

Morning TF

Yes, there was a lot of hopes in my post but Lindy has a habit of converting hope into reality. When has she not?

Of course, there are some things outside her control such as getting Ichor's IND approved. If Ichor had a development director with the attention to detail that Sally Adams has, then I am sure it would have been approved some time ago.

Also, there may be further delays to trials. Take the problems in manufacturing Modi1. But guess who sorted out the problems.

I think we all have to remember that this is new and complicated science and, as such, it is hard to implement.
SCIB2 has 16 targets! I can't imagine that will be easy to manufacture. It is also being delivered by nano vesicle. There are probably not many new drugs that have gone down this delivery route. Then you have the problem of maintaining the dual presentation using this delivery method. I suspect there will be 2 nano vesicles, one for the blood stream and one for the soft tissue.

You have a good weekend too.

Yes, and that CSO is useless. I hear she has applied for a job at VAL

There has been impressive progress since the last conference (looks like it is biennial)

1) SCIB1 combo trial may have started
2) MoDi1 trial close to starting we hope
4) SCIB2 combo trial close to starting we hope
5) Hopefully a GC win
6) Biontech collaboration
7) Karolinska collaboration
8) Modi2 being developed
9) Other news on other SCIB initiatives possibly
10) Possible news on the glycan platform

Wow!

Anyone notice that Victoria Brentville was a speaker at last year's conference giving an update of Immunobody and Moditope?

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928182/

Victoria Brentville (Scancell Ltd, Nottingham, UK) gave an update on the ImmunoBody® platform-based DNA vaccines which can induce high avidity T-cell responses to tumour-associated antigens (TAAs). Epitopes are engineered into the CDR3 region of immunoglobulin G (IgG). This is a whole antibody including the Fc region, which is absolutely necessary for function. The first clinical product is SCIBI, which has three epitopes from gp100 and one from TRP2 engineered into its CDR region. The vaccine alone has given a survival benefit in melanoma models (and patients), in combination with PD-1 antibodies, this effect is enhanced in murine models.

Their alternative approach depends on identifying suitable siPTMs and boosting them through a platform called moditope. This work has focused on the autophagy pathway for long-lived proteins which cause citrullination of arginine by Ca2+-dependent peptidylarginine deiminase (PAD) enzymes. This has led to the development of vimentin (VIM)-based citrullinated peptide-based vaccines that have been shown to be very effective in mouse models. A lead clinical target containing multiple such peptides is being developed.

Keith Flaherty.
I've heard that name somewhere!

Crumbs
What about the Genentech guy who said "Over my dead body".?
Somebody needs to take him out LOL
I could do with a holiday in California.

sorry wrong thread

The point about the GC is that it is another step (or stride) in Lindy's ambition to cure all cancer.
She is a pioneer, and as such she doesn't believe in pausing for breath.

It would have been easy to use Trigrid for the SCIB2 trial, but she chose to use Nano Vesicles because she considers this a better delivery system.

She probably has Modi3 all mapped out in her head already and has an inkling what Modi4 looks like.

And Sally Adams seems well capable of progressing whatever Lindy passes her way.